Patent · US Active

Composition of stem cells having highly expressed FAS ligand

US10098913B2 · kind B2 · utility

0Cited by

1References

13Claims

0Family size

Assignee

University of Southern California · US

Inventors

Songtao Shi · Los Angeles, US
Shiyu Liu · Mountain View, US
Fa-Ming Chen · Tainan, TW

Key dates

Filing date	Sep 10, 2014
Grant date	Oct 16, 2018
Priority date	—
Expiry date	Sep 10, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2502/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This disclosure relates in general to a stem cell treatment. This disclosure further relates to a stem cell treatment using a composition comprising stem cells having highly expressed Fas-L. This disclosure further relates to a stem cell treatment of multiple myeloma. This disclosure also relates to a composition comprising stem cells having highly expressed Fas-L. This disclosure also relates to preparation of a composition comprising stem cell having highly expressed Fas-L. This disclosure also relates to preparation of a composition comprising stem cells having highly expressed Fas-L by using a salicylate. An example of salicylate may be aspirin. This disclosure further relates to a stem cell treatment of multiple myeloma. This disclosure also relates to a stem cell treatment of an inflammatory disease and/or autoimmune disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.